Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

(2018) Mark C Genovese et al.   RHEUMATOLOGY

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

(2017) Maria Gabriella Raimondo et al.   Drug Design Development and Therapy

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

OP0051 Dipeptidyl-Peptidase-4 (DPP4) Characterizes A Subpopulation of Fibrosis-Promoting Fibroblasts and Is A Molecular Target for The Treatment of Fibrosis

(2016) A.M. Soare et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis

(2016) Eun Bong Lee et al.   CLINICAL PHARMACOKINETICS

Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis

(2016) Rayford R. June et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective

(2016) Peter C. Taylor et al.   RHEUMATOLOGY INTERNATIONAL

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo

(2014) Helen L. Wright et al.   RHEUMATOLOGY

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

(2013) Tom W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

(2010) Srinivasan Srirangan et al.   Therapeutic Advances in Musculoskeletal Disease

TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice

(2009) Antonio Marchesoni et al.   Annals of the New York Academy of Sciences